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 Abstract i 
Abstract 
Cancer evolves due to changes in DNA that give a cell an advantage at the 
expense of the remaining organism. These alterations range from individual 
base substitutions to broad losses or duplications of chromosomal material. 
This thesis explores how DNA and RNA sequencing can guide discovery of 
altered genes responsible for cancer development, profile the immune 
landscapes of tumors and support the diagnosis of difficult cases. 
 In the first of three studies, we examined DNA and RNA from the 
tumors of a patient with metastatic cancer but an uncertain diagnosis. We 
discovered that these tumors harbored a mutational signature associated with 
ultraviolet radiation. This restricted the possible sites of origin to those that 
can be exposed to sunlight. To confirm this, gene expression estimates were 
then compared to a large database of multiple cancer types. This gave a perfect 
match to cutaneous melanoma, thus enabling a certain diagnosis. 
 The second study established a method for searching candidate cancer 
genes that are altered by genomic copy number changes. The method 
integrates estimates of copy number changes with gene expression to prioritize 
genes concurrently and consistently altered with respect to both, putting 
greater emphasis on copy number changes comprising smaller chromosomal 
regions, which tend to exclude unselected genes from consideration. This 
system was able to retrieve known cancer genes as top candidates in several 
cancer types. In addition, this method also implemented a way to examine 
regions of DNA where genes are currently not known to exist. 
 In the final study, we molecularly profiled metastatic uveal melanoma 
(UM), a rare but difficult to treat eye cancer. We reintroduced a functional 
version of the tumor suppressor BAP1 into one deficient tumor, resulting in a 
global transcriptional shift towards a less metastatic subtype. We also found 
one tumor harboring a specific mutational signature that has not previously 
been observed in UM, and which might suggest a new risk factor. Next, we 
narrowed down a set of candidate genes potentially influencing tumor 
behavior via broad copy number changes, which could possibly be drug 
targets. Finally, we transcriptomically profiled tumor-infiltrating T-cells and 
found these to be in exhausted states, possibly explaining the failures of 
immunotherapy in UM. Despite this, they were in several cases capable of 
tumor recognition. 
 In conclusion, this thesis explores molecular data of cancers from a 
number of different angles. The results should have relevance for diagnostic 
principles and may suggest candidate genes for future functional studies. 
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Sammanfattning på svenska 
Cancer utvecklas på grund av förändringar i DNA som ger en cell en fördel på 
bekostnad av den övriga organismen. Dessa förändringar sträcker sig från 
substitutioner av enskilda nukleotider till större förluster eller dupliceringar av 
kromosomalt material. Denna avhandling undersöker hur DNA- och RNA-
sekvensering kan styra upptäckten av förändrade gener som ansvarar för 
cancerutveckling, profilera tumörers interaktioner med immunsystemet och 
informera diagnos i svåra fall. 
 I den första av tre studier undersökte vi DNA och RNA från tumörer 
hos en patient med metastatisk cancer men en osäker diagnos. Vi fann att dessa 
tumörer hade ett specifikt mönster av mutationer som associerats med 
ultraviolett strålning. Detta begränsade de möjliga ställen i kroppen i vilka den 
primära tumören kunde ha uppstått, till de som kan utsättas för solljus. För 
att bekräfta detta jämfördes genuttrycksnivåer sedan med en stor databas över 
flera cancertyper. Detta gav en perfekt matchning mot hudmelanom, vilket 
möjliggjorde en slutgiltig diagnos. 
 Den andra studien etablerade en metod för att söka efter möjliga 
cancergener som påverkas av förändringar i antalet underliggande DNA-
kopior. Metoden integrerar estimerade kopietalsförändringar med genuttryck 
för att prioritera gener som samtidigt och konsekvent förändras med avseende 
på båda. Den lägger samtidigt större vikt vid kopietalsförändringar som 
innefattar mindre kromosomala regioner, eftersom dessa tenderar att utesluta 
gener som inte selekteras av tumörer. Detta system kunde åternominera kända 
gener som toppkandidater i flera cancertyper. Utöver detta implementerade 
metoden också ett sätt att undersöka regioner av DNA där gener för 
närvarande inte är kända att existera. 
 I den slutliga studien genomförde vi en molekylär profilering av 
metastatiskt uvealt melanom (UM), en sällsynt men svårbehandlad 
ögoncancer. Vi återinförde en funktionell version av tumörsuppressorn BAP1 
i en tumör där denna gen inaktiverats av en mutation, vilket resulterade i ett 
globalt skifte i genuttryck i riktning mot en subtyp av denna cancer som har 
mindre metastatisk kapacitet. Vi fann också en tumör som hade en specifik 
mutationssignatur som inte tidigare har observerats i denna cancer, och som 
skulle kunna indikera en ny riskfaktor. Därefter kartlade vi gener som 
potentiellt skulle kunna påverka tumörers beteende via förändringar i antalet 
kopior av kromosomarmar, vilka eventuellt skulle kunna vara mål för riktade 
läkemedel. Slutligen profilerade vi genuttryck i individuella 
tumörinfiltrerande T-celler och fann dessa vara i utmattade tillstånd, en möjlig 
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förklaring till varför immunterapi inte fungerar i denna cancerform. Trots 
detta vara T-cellerna i flera fall kapabla att känna igen tumörer. 
 Sammanfattningsvis innefattar denna avhandling en undersökning av 
molekylär data från tumörer utifrån ett antal olika vinklar. Resultaten bör ha 
relevans för diagnostiska principer och kan möjligtvis föreslå gener av intresse 
för framtida funktionella studier. 
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Abbreviations 
 TCGA 
A Adenine ACC Adrenocortical carcinoma 
APC Antigen-presenting cell BLCA Bladder urothelial carcinoma 
C Cytosine BRCA Breast invasive carcinoma 
CAR-T Chimeric antigen receptor T-
cells 
CESC Cervical squamous cell carcinoma and 
endocervical adenocarcinoma 
CM Cutaneous melanoma CHOL Cholangiocarcinoma 
CNV Copy number variant COAD Colon adenocarcinoma 
CUP Cancer of unknown primary DLBC Diffuse large B-cell lymphoma 
DC Dendritic cell GBM Glioblastoma multiforme 
DNA Deoxyribonucleic acid KICH Chromophobe renal cell carcinoma 
DNA-seq DNA-sequencing KIRC Kidney renal clear cell carcinoma 
FFPE Formalin-fixed paraffin 
embedded 
KIRP Kidney renal papillary cell carcinoma 
LGG Brain lower-grade glioma 
G Guanine LIHC Liver hepatocellular carcinoma 
HLA Human leukocyte antigen LUAD Lung adenocarcinoma 
Indel Insertion or deletion MESO Mesothelioma 
LOH Loss of heterozygosity OV Ovarian serous cystadenocarcinoma 
MHC Major histocompatibility 
complex 
PAAD Pancreatic adenocarcinoma 
PCPG Pheochromocytoma and paraganglioma 
mRNA Messenger RNA PRAD Prostate adenocarcinoma 
NK Natural killer (cell) READ Rectum adenocarcinoma 
PDX Patient-derived xenograft SARC Sarcoma 
RNA Ribonucleic acid SKCM Skin cutaneous melanoma 
RNA-seq RNA sequencing STAD Stomach adenocarcinoma 
SNV Single nucleotide variant TGCT Testicular germ cell tumor 
T Thymine THCA Thyroid carcinoma 
TCGA The Cancer Genome Atlas THYM Thymoma 
TCR T-cell receptor UCS Uterine carcinosarcoma 
U Uracil UCEC Uterine corpus endometrial carcinoma 
UM Uveal melanoma UVM Uveal melanoma 
UV Ultraviolet (radiation)   
WES Whole exome sequencing   
WGS Whole genome sequencing   
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1 Introduction 
Cancer arises due to the corruption of normal cells by changes in the cellular 
DNA. These changes can occur due to inherited DNA maintenance 
deficiencies, age-associated accumulation of mutations or exposure to 
exogenous mutagens, such as certain chemicals or radiation. Cancer cells grow 
in a disordered fashion to form masses called tumors, due to the inactivation 
of control mechanisms that normally prevent this. The host immune system 
has the capacity to recognize most rogue cells and eliminate them. However, 
cancer cells eventually tend to develop evasion mechanisms and become 
resistant. As the cells keep dividing, they gradually acquire additional genomic 
changes that may provide them with the ability to migrate and settle in new 
locations of the body: they metastasize.  
 Metastatic disease is very difficult to treat. On one hand, cancers that 
spread may hide in obscure places. On the other, they often evolve 
independent drug and immune resistance mechanisms. For these reasons, 
treatments may eliminate a fraction of the tumors, while unresponsive clones 
often remain in the body. In some cases, cancers may metastasize before the 
original tumor is discovered, leaving few effective treatment options. In a 
fraction of these instances, the original tumor and the type of cancer the 
patient is affected by cannot be determined. 
 Cancers arising from different tissues and in different patients are 
unique diseases. The underlying causes, mutations and cellular behaviors vary, 
and drugs found to be appropriate for one cancer may have no use on another. 
The success of cancer treatment is also dependent on the status of the patient’s 
immune system. Eventually, mechanisms that are in place to prevent harmful 
long-term immune reactions activate, and consequently reduce the ability to 
destroy the cancer cells. Therefore, treatment needs to be tailored to the 
unique conditions of each patient for an optimal response. 
 The goal of cancer genomics is to profile the genetic changes that occur 
in tumors, to discover the mutations that cause the cells to behave erratically, 
determine the underlying risk factors and to search for tumor vulnerabilities 
that may provide an opportunity to eliminate them. 
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1.1 The human genome 
The human genome is composed of approximately 3 billion pairs of 
nucleobases, which constitute the double stranded nucleic acids known as 
DNA (deoxyribonucleic acid). The nucleobases are each members of the four-
letter alphabet adenine (A), cytosine (C), guanine (G) and thymine (T) (Fig. 
1a)1. A and G derive from a class of compounds termed purines, while C and 
T correspond to pyrimidines. DNA is double-stranded and composed of pairs 
between A, C, G, T in one strand and T, G, C, A in the other complementary 
strand, respectively (Fig. 1b-d)1. Human DNA is partitioned into separate 
large units termed chromosomes, of which there are 23 pairs, in addition to a 
separate sequence of mitochondrial DNA. 
 The genome encodes instructions for making the proteins that govern 
the biochemical reactions, and thereby the appearance and behavior, 
(phenotype) of the cell, in units called genes1. These genes are transcribed by 
enzymes called RNA polymerases that create ribonucleic acid (RNA) 
sequences, also called transcripts, reflecting their original sequences. RNA is a 
similar molecule to DNA, but tends to be single-stranded and also substitutes 
the base T for uracil (U) (Fig. 1d)1. The set of RNAs produced from the 
genome is termed the transcriptome. A large fraction of these transcripts are 
then translated to protein sequences (Fig. 1d) by molecular complexes called 
ribosomes. These are termed messenger RNAs (mRNAs). Those that are not 
are called non-coding RNAs. Translation uses triplets of nucleotides, which 
can theoretically be decoded in three partially overlapping reading frames, to 
determine which amino acids are incorporated into proteins. A given gene can 
encode instructions for multiple different variants of a protein (isoforms), 
which is possible due to a mechanism called alternative splicing. This process 
functions by joining the different coding regions, exons, of a gene in different 
ways. The consequence is the exclusion or inclusion of different sets of exons, 
leading to the production of different mRNA sequences1. 
 The genome is replicated and partitioned into two daughter cells at 
each cell division. Although, a certain number of small errors always occurs, 
leading to mutations accumulating during aging. At each cell division, the 
ends of the chromosomes, telomeres, also progressively shorten, since they are 
difficult to fully replicate each time2. When the telomeres are short enough, 
the cells enter a state called senescence, and cease to divide. This is beneficial, 
since cell division and improper repair mechanisms acting on chromosomes 
with compromised telomeres can lead to genomic instability, which could 
eventually could cause cancer2. Cancerous cells, however, tend to avoid 
senescence by expressing proteins that regenerate telomere sequences, which 
are otherwise only expressed in specific cell types, such as stem cells2. 
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 Besides genes, the human genome also contains a large number of 
regulatory elements. These include the core promoter regions adjacent to the 
transcription start sites of genes, where transcription factors and polymerase 
bind to initiate transcription3. In addition, regions known as enhancers exist, 
which also bind transcription factors, and can increase the transcription 
frequency of nearby genes3. Silencers, on the other hand, can instead recruit 
repressive factors3. The regions of the genome influenced by such elements are 
restricted by the presence of insulator sequences, which act as boundaries3. 
Various types of so called epigenetic DNA modifications, for instance 
methylation and chromatin conformation changes, also influence the 
transcription of genes. These modifications can be either activating or 
repressive4. Combined, these elements and alterations provide a wide variety 
of possibilities to regulate expression, making it possible for cells from different 
tissue types to display widely different phenotypes, despite sharing the same 
underlying DNA. 
 The basic sequence of the human genome was determined by the 
Human Genome Project and published in a first preliminary version in 20015. 
This reference sequence continues to be improved as technological 
enhancements are made that allow for more precise reconstruction. However, 
each individual has a unique genome, containing a large number of inherited 
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changes, some of which are particular to certain populations6. The sequencing 
of many additional genomes in recent years, such as by the 1000 Genomes 
Project, have made it possible to construct databases of normal human DNA 
variants7. Understanding the structure of the normal human genome is of 
fundamental importance for identifying the genomic changes that give rise to 
cancer cells. 
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1.2 The cancer genome 
Damage to DNA during cell division or due to external factors can cause any 
of the bases in the normal genome to be substituted for another one, called 
single nucleotide variants (SNVs, Fig. 2a), or additional bases to be inserted 
or deleted (indels, Fig. 2b). The latter can cause a shift in the natural reading 
frame of a gene, leading to irrelevant amino acids being incorporated into the 
translated protein. Some mutations can occur in germ cells and be inherited. 
Those that occur elsewhere in the body are termed somatic mutations. Many 
base substitutions do not alter protein sequences, since multiple codons exist 
that correspond to the same amino acids, i.e., they are degenerate. These 
mutations are called synonymous, whereas those that influence protein 
composition are termed non-synonymous. 
 New variants of the proteins encoded by mutated genes may have 
different properties. In some cases, they could provoke the cell to constantly 
signal for cell division. Altered genes that operate in this manner are called 
oncogenes, whereas their normal counterparts are called proto-oncogenes. In 
other cases, proteins that act as natural breaks on replication or contribute to 
other mechanisms preventing cancer development, such as through DNA 
repair, may lose their function8. These are termed tumor suppressors. 
 A cell can also suffer a larger error during cell division, which in turn, 
may cause wide sections of chromosomes to be lost, or gained in multiple 
copies. Such DNA copy number changes can be broad, sometimes affecting 
entire chromosome arms, or focal, limited to a relatively small number of genes 
(Fig. 2c-d). The result can be overexpression or loss of expression of the 
affected genes8. In the latter case, such events may also be coupled with 
mutations, which together inactivate a tumor suppressor and thereby triggers 
unrestrained growth, termed loss of heterozygosity (LOH). Genomic 
instability can also lead to the creation of fusion genes, as a consequence of 
genomic rearrangements (Fig. 2e). This can result in a new abnormal protein 
that changes cell behavior, and which can thereby act as an oncogene. 
However, such events can also lead to tumor suppressor dysfunction9. In 
addition, tumor suppressors may also be inactivated, or oncogenes 
overexpressed, as a result of viral infections. These viruses may also carry their 
own oncogenes into the cell10. 
 Identifying oncogenes and tumor suppressors is of great importance, 
since the proteins they encode or the biochemical signaling pathways they 
affect can potentially be targeted with drugs. Targeting unique mechanistic 
dependencies in cancer cells can help to eliminate tumors while sparing normal 
cells. Identification of such genes largely demands that the genomes of many 
tumors are compared side by side to find consistent alterations in a genomic 
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region. Overrepresented genomic events can indicate that these give the tumor 
a selective advantage, which in turn could suggest that the tumor might 
depend on the affected genes11. For instance, in cutaneous melanoma it has 
been found that the gene BRAF is mutated at the exact same nucleotide in over 
half of all patients, giving rise to a new hyperactive version of the protein it 
produces, which can promote cell division12. This has led to the development 
of a compound that inhibits the activity of the mutated protein, which has 
been successful in prolonging the survival of patients13. 
 Cellular development is also influenced by the epigenetic state of 
DNA. This refers to non-nucleotide modifications of the genome, such as 
changes in its three-dimensional organization or the attachment of certain 
molecules to DNA, which can determine what regions that are open for 
transcription or alter the activity of regulatory elements, such as enhancers. 
Common epigenetic modifications are those that attach or remove methyl, 
acetyl or phosphoryl groups from structural units called histones. Besides 
regulating transcription, these changes can also have an impact on DNA 
repair. Several known oncogenes and tumor suppressors are involved in such 
modifications14. Since cellular specialization in the formation of different 
organs largely depends on changes in epigenetic state, cancers that arise from 
different organs and tissues also tend to possess different epigenetic landscapes. 
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In addition, differences can often also be found among subtypes of the same 
cancer15,16. Some tumors contain relatively few, if any, recurrent mutations, 
but instead seem dominated by epigenetic alterations. This is the case for a 
number of pediatric cancers14. Epigenetic state transitions are more common 
among cells in very young children, due to the active development of organs, 
which could potentially explain the overrepresentation of seemingly 
epigenetically driven cancers in this group. 
 An important American initiative, The Cancer Genome Atlas 
(TCGA), has performed sequencing of over 10000 genomes from 33 cancer 
types, and profiled their gene expression patterns and epigenetic states. This 
research has been made available to researchers worldwide and has 
tremendously progressed our understanding for the genomic characteristics of 
cancer cells. It has also made it possible to identify several new causal genes, 
for which drugs either have been developed or might be in the future. In 
addition, this data has led to more accurate ways of classifying tumors, on a 
genetic basis, which can improve prognostics and clinical decision-making15,17. 
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1.3 Determining genome and transcriptome 
composition 
The composition of DNA and RNA can be determined in a high-throughput 
manner with sequencing technologies. In a common approach, DNA is first 
shattered into short fragments, adapter and index sequences added to first 
facilitate amplification of the fragments, then immobilization within the 
instrument and later identification of the sample that the sequences originated 
from, in cases where multiple samples are analyzed simultaneously. Sequences 
complementary to the immobilized and amplified single-stranded fragments 
are then synthesized one nucleotide at a time. The nucleotides are tagged with 
chemical groups that lead to the generation of light signals as they are added, 
which allows the instrument to register their identity. Some methods use other 
approaches, such as the emission of hydrogen ions, in order to register added 
nucleotides. This allows reconstruction of the original sequences. RNA is 
analyzed similarly, but first needs to be reverse transcribed to complementary 
DNA18. The results are millions of short “reads”. Alternatively, each fragment 
can also be sequenced from both ends, yielding pairs of reads.  
 These then need to be mapped to a reference sequence of the genome 
of the studied organism, using computational methods. Mismatches to the 
reference may indicate somatic or inherited DNA variants. The paired-end 
approach can be beneficial for reconstructing splice variants of RNA, 
determination of structural rearrangements in DNA, expressed fusion genes 
or viruses that have integrated themselves into the genome. 
 Different strategies can be applied for genome sequencing. The two 
methods employed in this work are whole exome sequencing (WES) and 
whole genome sequencing (WGS). WES is targeted towards the coding 
regions of genes, the exons. WGS targets the whole human genome, including 
the intronic regions of genes, which do not carry over to the protein sequence, 
as well as “intergenic” regions, which do not contain known genes. While 
WGS is theoretically preferable, using this technique is not always 
economically feasible. Still, the cost of sequencing a whole genome has 
decreased substantially from over $0.5-1 billion spent on the first human 
genome to less than $2000 presently6. For clinical purposes, it is also possible 
to perform targeted sequencing of specific genes that are both known to be 
altered in cancer and therapeutically actionable. 
 For transcriptome analysis, the corresponding method is termed RNA-
seq and only covers actively transcribed exons. Different strategies can be used 
to prioritize different subsets of RNA molecules. For instance, one may deplete 
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ribosomal RNAs before sequencing, since these tend to be very abundant and 
rarely of interest. Another option is to only sequence transcripts with a poly-
A tail, which will capture the majority of protein-coding RNAs, but miss many 
non-coding ones19. An earlier method for gene expression analysis was the 
microarray, which gives quantitative output, but not the sequences of 
transcripts. A visual comparison of WES, WGS and RNA-seq reads aligned to 
the human genome is shown in Fig. 3, highlighting a frameshift deletion in 
the tumor suppressor BAP1. 
GCAATCTCAGCCTCCACACACTTCAGCAGTGCCAGCAGCT
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Figure 3. Reads (gray) aligned to the human genome, from exome (WES), whole 
genome (WGS) and RNA sequencing (RNA-seq), respectively, at the position of the 
tumor suppressor BAP1. The lower panel shows a zoomed-in view of a position with 
a small deletion in this gene, which leads to a frameshift upon translation. The 
consequence is very likely to be a non-functional protein. 
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1.4 Genetic alterations that drive cancer development 
The genes or genomic alterations that are responsible for the creation of 
tumors are collectively referred to as drivers11. These may allow the cancer cell 
to replicate beyond normal cellular limits, metastasize to new locations in the 
body, promote the growth of new blood vessels supplying a tumor with 
nutrients, reprogram its metabolism, or make it unresponsive to attacks by the 
immune system or drugs used for cancer treatment. In addition, the altered 
activity of such genes may compromise the genetic stability of the cell, 
facilitating new mutations and genomic rearrangements that can alter cellular 
behavior and allow it to adapt to new circumstances20. The characteristic 
biological rewiring that occurs in cancer cells have been divided into what is 
known as the hallmarks of cancer, summarized in Table 120. To gain these 
hallmarks, only a few important genes may need to be altered11,21. The 
majority of mutations that occur in cancer are inconsequential, and referred 
to as passengers. Driver genes can, in addition to the hallmarks in which they 
participate, also be subdivided based on the types of genomic changes by 
which they are activated or inactivated. The following sections describe this in 
more detail, focusing on the most common classes of driver alterations, as well 
as approaches that may be used to identify genes of interest. 
1.4.1 Base substitutions and indels 
Oncogenes and tumor suppressors altered by base substitutions or indels are 
referred to as mutational drivers. In the case of oncogenes, these events 
commonly occur at specific “hotspots” in the gene, which may, for instance, 
disrupt a protein domain critical for interaction with a negative regulator, 
make them independent of otherwise necessary ligands for activation or 
prevent them from binding inhibitory drugs8,21. They may also give the gene 
entirely new functions21. Tumor suppressors, on the other hand, tend to be 
affected by a wider range of mutations that either cause dysfunction of a 
specific domain, a large truncation of the protein or indel-induced shifts in 
reading frame22. However, biologically relevant inactivation typically requires 
that both alleles are mutated, whereas one allelic event can be sufficient to 
activate an oncogene11,23. The exceptions are haploinsufficient tumor 
suppressors, where only one allele needs to be altered in order for the cancer 
to gain an advantage24.  
 Mutations can also alter the splicing of transcripts, leading to retention 
of intronic sequences, which can prohibit complete translation. Such 
mutations may also cause exons to be either added or spliced out of the 
resulting transcript, which can alter protein function25-27.  In addition, a  
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Table 1. Characteristic traits of cancer cells that have become known as the 
hallmarks of cancer, as a result of an influential review article of the same name20. 
Hallmark Description 
Induction of proliferative signaling Growth factor availability limits cell division. 
Cancer cells may reduce their dependence 
on these, produce their own, provoke other 
cells to produce them or inactivate negative 
feedback mechanisms restraining their use. 
Inactivation of anti-proliferative mechanisms Checkpoint mechanisms prevent 
inappropriate replication if the right 
conditions are not met, for instance, if the 
genome is damaged. Cancer cells can 
deactivate such mechanisms. 
Replicative immortality Cells are limited in the number of 
replications they can undergo, closely 
related to chromosomal telomere length. 
Upregulation of enzymes regenerating 
telomeric sequences can counteract this. 
Resistance to cell death Mechanisms are in place to trigger cell 
death upon various cellular crisis states, 
which can become deactivated in cancer 
cells. 
Genomic instability Cancer development and evolution relies on 
the accumulation of mutations and other 
genomic alterations, caused by failures in 
genome maintenance and mutagenic 
exposures. 
Angiogenesis Tumors can produce factors that induce the 
growth of new blood vessels, which provide 
nutrients and oxygen needed for cellular 
metabolism and replication. It additionally 
allows them to get rid of metabolic waste 
products. 
Metabolic rewiring Cancer cells adapt their metabolism to 
constantly supply energy required for 
replication, commonly by high rates of 
glycolysis (even under aerobic conditions). 
Inflammation Inflammation-associated factors can 
promote growth, survival, angiogenesis and 
an epithelial to mesenchymal transition 
(associated with metastasis). 
Immune evasion The immune system normally recognizes 
and kills transformed cells. Expression of T-
cell inhibitory molecules or defective antigen 
presentation can interfere with this28. 
Invasion and metastasis Loss of intercellular adherence and specific 
changes in phenotype enables migration 
and adaptation to new environments, which 
makes it possible for the tumors to spread. 
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mutation may a create a new splice site within an exon, leading to a truncated 
version being included. Splicing defects can also be a mechanism that activates 
oncogenes, for instance by the skipping of exons that encode protein domains 
enforcing ligand-dependence27. An interesting case illustrating the potential 
consequences of alternative splicing is the oncogene BRAFV600E, where the 
preferential expression of a particular transcript variant has been found 
associated with drug resistance29. 
 Mutations can be detected in a tumor by mismatches that occur as 
sequencing reads are aligned to a reference genome. However, artifactual base 
changes can occur in reads due to issues with sequencing or alignment30. 
Accurate alignment is also challenging in certain sequence contexts of the 
human genome. For these reasons, methods need to be used that can 
statistically model which estimated mutant allele frequencies are relevant for 
considering a variant a true positive in different contexts30.  
 In addition, a large number of discovered mismatches to the reference 
will be normal population variants that are not specific to the cancer. 
Therefore, it is beneficial to also sequence normal cell material from a patient, 
which makes it possible to filter out healthy genome variation and determine 
which mutations are somatic. Such control samples can also aid in detecting 
artifactual variant calls. Databases of common population variants are also 
available7,31, which can allow further discrimination, or partially substitute 
when normal material is not available.  
 A challenge here is also the fact that tumors tend to contain varying 
amounts of normal cells from adjacent tissue, as well as immune cells. This 
can cause some mutations to occur in a smaller fraction of reads than expected 
for a pure sample, making them difficult to detect with accuracy. Furthermore, 
tumors often contain various subpopulations, known as sub-clonal cells, which 
possess different sets of mutations, contributing to the issue. Mutant allele 
frequencies are also influenced by DNA copy number changes. For this reason, 
methods developed for genotype calling of healthy individuals are generally 
not sufficient. Fortunately, however, a number of specialized tools have been 
developed that are able to statistically assess the influence of these confounding 
factors32-34. 
 Next is the issue of discriminating driver mutations from the 
numerous passenger events that occur in cancer genomes. For this purpose, 
one may statistically test whether or not a given genomic element is mutated 
more frequently than can be expected by chance, which could indicate that 
the event is under positive selection. However, a factor to be accounted for is 
that different genomic contexts have different probabilities to undergo 
mutation. For instance, long genes and late replicating genomic regions will 
tend to accumulate a larger total number of mutations than others35. 
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Therefore, indications of unexpectedly high recurrence may also be found if 
the model of what to expect is not accurate. Some methods used for 
nominating events under potential selection therefore also take into account a 
number of covariates that influence mutation rates35,36. However, these 
methods tend to require large sample sizes to be successful, which are not 
always available. 
 Significantly recurrent mutations in a given cancer type frequently 
display patterns of mutual exclusivity (Fig. 4). This can indicate that only one 
of them in a given tumor is sufficient to provide the cancer with the necessary 
advantage. Often such patterns have been found for genes that participate in 
the same biological pathways. For this reason, mutual exclusivity can provide 
additional evidence that a mutation or gene may be a cancer driver, in addition 
to potentially suggesting new mechanisms the gene could be involved in37. 
1.4.2 Copy number changes 
Besides mutations, a frequent means of altering gene activity is via their 
duplication or loss in DNA. Detection of such copy number changes can be 
done with either WGS or WES. Another common approach uses single 
nucleotide polymorphism (SNP) microarrays. In the former, differences in 
genomic read coverage compared to normal control samples are used to 
discover changes38. In the latter, fragmented and fluorescently labeled DNA 
binds to oligonucleotide probes of common heterozygous genetic variants 
along the genome that are immobilized on a microarray. Signal intensities 
associated with binding to probes corresponding to different alleles can then 
50% GNAQ
44% GNA11
31% BAP1
22% SF3B1
12% EIF1AX
4% COL14A1
4% CYSLTR2
4% MACF1
4% MUC16
4% TTN
Nonsense mutation
Frameshift insertion
Missense mutation
Non-frameshift deletion
Multiple events
Frameshift deletion Splice site
Figure 4. Recurrency and mutual exclusivity patterns of non-synonymous mutations 
in primary uveal melanoma (data from TCGA). The ten most frequently mutated 
genes in the cohort of 80 patients (columns) are shown. GNAQ, GNA11, BAP1, 
SF3B1, EIF1AX and CYSLTR2 are considered mutated more frequently than can 
be expected by chance, taking into account covariates such as gene length. The 
mutual exclusivity patterns displayed by some of these also indicate that they may 
have effects that can substitute for each other in driving development of this cancer. 
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be used to assess the presence of broad shifts in estimated allele frequencies39,40. 
With both technologies, ratios relative to the expected normal scenarios are 
then segmented using a specialized algorithm in order to determine 
continuous copy number-altered regions. 
These events can cause overexpression of oncogenes, 
underexpression, LOH or complete deletion of tumor suppressors. As with 
recurrent base substitutions, recurrency can also be indicative of genes under 
selection within regions of somatic copy number variants (CNVs)41. However, 
CNVs tend encompass a large number of genes, making it difficult to 
discriminate drivers from passengers. To better pinpoint those genes, one may 
take advantage of the fact that some tumors of a given cancer types may possess 
more size-limited (focal) events, which exclude most of the irrelevant 
candidates. In large cohorts, one may spot patterns that tend to narrow in on 
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Figure 5. Copy number changes in breast cancer genomes sequenced by TCGA. 
Red indicates genomic regions that have been gained in multiple copies, with color 
intensity proportional to the number of additional sequences, whereas blue indicates 
regions where either one or two alleles have been lost. Each row represents one 
tumor and patient. The large number of aberrations indicates high levels of genomic 
instability. Some events occur at nearly the same position in a large number of 
cases. As an example (lower panel), recurrent focal copy number gains occur on 
chromosome 17 at the position of the oncogene ERBB2. 
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a very specific region, containing only a few genes. Such is the case for ERBB2 
in breast cancer (Fig. 5), which has since been identified as an oncogene 
activated by the resulting overexpression in about 20-30% of tumors42. This, 
in turn, has led to the development of a successful drug that inhibits the 
encoded protein42. 
 However, not all recurrent copy number changes are indicative of 
positive selection. Tumors with high levels of genomic instability may display 
such patterns by chance. To avoid false positives, as with mutations, one may 
therefore statistically assess whether the changes in a given region are more 
frequent than random expectation. One commonly used algorithm for this 
purpose first calculates an empirical model of somatic CNV background rates, 
to which different genomic regions are then compared to derive a significance 
estimate. This is followed by a second algorithm that delineates specific regions 
of peak recurrence43. 
 Although this provides a statistical basis for determining copy number 
aberrations under selection and can lead to the nomination of convincing 
targets in some cases, many peak regions still encompass a large number of 
genes. Therefore, approaches that integrate additional data for each gene may 
be required to narrow the search space further. Commonly, one tests for 
correlations between changes in gene expression and copy number, since this 
is the most likely way that a copy number aberration will mediate a selective 
advantage.  
A remaining difficulty is defining potential candidates in the cancer 
types that almost exclusively display chromosome arm-wide copy number 
changes, such as uveal melanoma16. In these cases, no informative regions of 
minimal overlap exist. There is also the possibility that these events do not 
target single genes, but rather groups that participate in specific pathways44. 
Yet another hypothesis is that they have no target at all, but rather confer an 
advantage via aneuploidy alone, although some literature suggests that the 
latter might have a negative impact on fitness44-47. 
1.4.3 Gene fusions 
A third major class of genetic drivers arises from the merging of material of 
different genes. These so-called fusion genes can encode chimeric proteins that 
either have entirely new functions or the ability to be expressed at higher levels. 
They may also maintain constitutive activation due to acquired or lost protein 
domains that naturally either promote or restrain their actions48,49. Fusions are 
caused by chromosomal rearrangements, which may occur due to adverse 
events during DNA repair or cell division50. Such events may also cause the 
translocation of genes to regions that are more or less permissive to 
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transcription, as determined by nearby regulatory elements48. Less well studied 
is the phenomenon of transcription-induced gene fusions, where mistakes in 
transcription or splicing merges material from two, most often nearby, 
transcripts48. These do not appear particularly recurrent or cancer-specific, 
however, making it unlikely that they have any major role48. Many fusion 
genes encode kinases, which may be possible to target with existing inhibitors, 
making their identification a priority49. 
 Recurrent fusions can be found in several cancer types. For instance, 
BCR and ABL1 are often joined in myeloid leukemia, whereas fusions between 
FGFR3 and TACC3 are prevalent in glioblastoma multiforme, as well as other 
cancers, while TMPRSS2 is fused to ERG in up to 38% percent of prostate 
adenocarcinomas sequenced by TCGA9. 
 Fusions can be detected by analysis on either WGS or RNA-seq data, 
although using both approaches can improve specificity9,48. In these cases, it is 
beneficial to use paired-end sequencing, since the different ends of a given 
fragment may be found to map to exons of two different genes. As always, it 
is also useful to sequence a non-cancer sample from the same patient, in order 
to determine whether the discovered fusions are somatic. Another way these 
methods complement each other is that RNA-seq allows for assessing effects 
on expression of each partner gene, whereas WGS can reveal structural 
rearrangements that do not manifest as gene fusions. 
1.4.4 Cancer viruses 
Latent cancer genes can also be activated or deactivated by viral infections. 
Currently, seven, or potentially eight, viruses are known to be involved in 
human cancers10,51. To corrupt the cell into an efficient factory of viral 
particles, and in some cases integrate into its DNA, they must overcome the 
host’s defense mechanisms. Some of these mechanisms are also important in 
preventing tumor formation. For instance, most of these cancer viruses express 
oncogenes that inhibit cell cycle and DNA damage checkpoints controlled by 
the tumor suppressors RB1 and P53, the latter being the most commonly 
mutated gene in human cancer and a regulator of several pathways relevant to 
cancer hallmarks10,52. Accumulation of genomic damage as a result of 
dysfunctional checkpoint mechanisms can further enable mutation-induced 
activation of other cancer-associated genes.  
 There are also other means by which viruses can induce mutations, for 
instance via provoking aberrant activity of activation-induced cytidine 
deaminase (AID), a cellular protein with the explicit function of mutating 
DNA, which is normally used for diversifying the sequences of B-cell 
receptors. Inappropriate AID activity can be seen in several cancers, and is 
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associated with specific patterns of C > G and C > T mutations across the 
genome53,54. Some viral proteins can also promote migration and invasion10, 
possibly enabling further distribution of viral particles. Tumor development 
can also be enabled by virus-associated chronic inflammation10. 
 In the case of those that are able to integrate into the host genome, the 
viral sequences may contain enhancers or promoters that lead to the 
overexpression of oncogenes close to the integration site, achieve the same end 
goal by disrupting local regulatory elements, or transform proto-oncogenes via 
fusions with viral sequences51,55-58. This is known as insertional mutagenesis. 
Similarly, regulatory or sequence alterations in tumor suppressors may lead to 
their inactivation. Furthermore, some viruses may integrate cellular proto-
oncogenes into their own genetic material and transform them to actively 
oncogenic variants55,58. 
 The presence of viral sequences in cancer cells can be detected by 
examining reads that do not fully align to the human genome, which can then 
be searched for better matches among genetic material from viruses56,57,59. 
Reference independent (de novo) assembly of non-human reads can also first 
be done to find contiguous sequences, which may be more easily mapped 
foreign genomes60. Virus detection would also be a situation were paired-end 
reads are more valuable, since they would better allow the detection of fused 
human-viral sequences.  
 Finally, while computational methods can identify genes, mutations, 
chromosomal rearrangements and viruses that are likely to be positively 
selected by tumors, functional experiments are always required to confirm 
their hypothesized roles in cancer development and progression. 
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1.5 Causes of mutations 
Damage to cellular DNA can occur as a result of external genotoxic exposures, 
or due to internal biological processes. Among the external factors are certain 
types of radiation, chemicals and viral infections. Among internal causes are 
inherited defects in DNA replication or repair, reactive oxygen species 
associated with metabolic stress or inflammation, as well as natural errors that 
occur during DNA replication in every cell division61. Most mutations are of 
little consequence, but accumulate with age, increasing the risk of cell eventual 
cell transformation. A number of these factors can be influenced by personal 
decisions regarding, mainly, sun exposure, smoking, alcohol consumption, 
physical activity and diet61. 
 The implication of risk exposures has traditionally relied on 
epidemiological studies and findings that specific occupations or habits have 
been overrepresented among victims of certain types of cancer, which, for 
instance, led to the discovery of compounds in cigarette smoke as potent 
carcinogens58. However, the recent contributions from large-scale sequencing 
projects have enabled new ways to study the potential causes of cellular 
mutations.  
 Besides the possibility of statistically assessing relations between cancer 
incidence and individual heritable variants across the human genome, it has 
also been found that different carcinogens and biological processes are 
associated with non-random occurrences of mutations along the genome. This 
has made it possible to define unique genomic mutational signatures that recur 
across many tumors. Combined with information about known exposures and 
genomic profiling of inherited variants, these patterns can be highly suggestive 
about potential underlying causes53. 
1.5.1 Mutational processes and their signatures 
Passenger mutations may not contribute directly to cancer development, but 
their genomic distributions can serve as fingerprints for the processes that have 
been operative53. For instance, C > T and CC > TT mutations have long been 
known to be common in cutaneous melanoma and other skin cancers53,62. 
These are caused by UV-induced dimer formation between adjacent 
pyrimidines (C or T), and subsequent failure to repair these lesions before 
DNA replication63. The most common variants are cyclobutane pyrimidine 
dimers (CPD) and 6–4 pyrimidine–pyrimidone (6-4PP)63. Since their repair 
partly depends on a mechanism coupled to transcription, a bias can be seen 
for mutations on the untranscribed strand53,64. Individuals with inherited 
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defects in nucleotide excision repair also have a predisposition for developing 
various skin cancers63. 
 However, there are also other processes that can cause C > T 
mutations. For instance, methylated cytosines (5-methylcytosine) may 
undergo deamination spontaneously, transforming them to thymine, which 
may then fail to be corrected by repair mechanisms65. In addition, it is likely 
that multiple mutational processes have operated on the genetic material of a 
given tumor.  In order to separate the contributions of such processes, one 
may take advantage of the fact that the local sequence context can often 
influence the probability of substitutions66. A landmark study examined the 
mutation frequencies of each among the 96 possible triplets of adjacent 
nucleotides that contain the altered base as its central component in over 7000 
cancers of diverse types53. By a clustering technique known as non-negative 
matrix factorization (NMF), they were able to distinguish 21 independent 
components of the overall mutation spectra of the tumors, and their 
associations with different cancer types.  
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Figure 6. Five mutational signatures which have been found associated with 
specific mutational processes and/or carcinogens. The y-axis indicates the two 
bases adjacent to the one that is substituted, which together are referred to as a 
trinucleotide. Different trinucleotide contexts have different probabilities to undergo 
mutations, depending on the process generating the substitutions. This can make 
some signatures useful for discovering new carcinogens or as a biomarker for what 
may have caused the cancer, and in some cases also where in the body the tumor 
may have originated from. Data for this figure was obtained from 
https://cancer.sanger.ac.uk/cosmic/signatures (accessed 04-12-2018). 
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 One of these matched well with prior knowledge of UV-induced 
mutations, whereas a separate pattern emerged that was compatible with 
spontaneous deamination of methylated cytosines, the latter of which was also 
found correlated with the age of diagnosis53. Moreover, the analysis also 
revealed signatures that preferentially occurred in individuals with the habit of 
tobacco smoking, those exposed to the alkylating anti-cancer drug 
temozolomide, carriers of mutations in the DNA repair-associated genes 
BRCA1 or BRCA2, aberrant activity of the cytidine deaminase AID and similar 
proteins, as well as other patterns that could be tied to specific exposures53. 
Some of these are shown in Fig. 6.  
 Later studies have since extended this work by defining novel 
signatures or associations with potential risk factors15,67. Important to keep in 
mind, however, is that an association is not a proof of cause. Although the 
mechanisms that give rise to some of these signatures are well established, 
further experiments are needed to delineate the exact processes behind the 
majority. In addition, while the NMF method may be successful with cohorts 
the size of TCGA, smaller scale studies may not enable the full separation of 
patterns that are simultaneously present in tumors53. 
 Nonetheless, screening of tumors for already known signatures can still 
be done with as little as one sample, and given the occasionally strong 
associations with particular exposures or cancer types, these patterns may be 
repurposed as biomarkers. To do so, one method is to search for the non-
negative linear combination of known signatures that best explains the overall 
mutation spectrum in a tumor68. 
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1.6  Transcriptomics in cancer research 
The gene expression patterns in cancer cells are shaped by a multitude of 
factors, including the cell origin, copy number alterations and the activities of 
oncogenes and tumor suppressors15. Different cells may share the same 
genome, but epigenetic diversification during development, such as 
methylation or other histone modifications, can lead to large transcriptomic 
differences. Besides protein coding genes, the genome also encodes at least as 
many actively transcribed non-coding RNAs (although some studies argue 
that sizeable fractions of them may in fact produce small peptides69,70), which 
are also often expressed in a tissue-dependent manner71. As the convergence of 
all these factors, the transcriptome can be argued to yield a snapshot of the 
cell’s phenotype at a given time point. RNA-seq can therefore be used to 
answer a wide range of biological questions. 
 A frequent use case is the comparison of differences in gene expression 
between groups of samples, commonly cell lines, subjected to varying 
experimental treatments. This may be done to determine mechanisms 
involved in response to drugs, genetic perturbations or for discovering 
biomarkers. RNA-based biomarkers may be measured in patient material and 
used for prognosis and determining the most suitable course of action. As an 
example, the eye cancer uveal melanoma can be divided into two broad 
subtypes, which are associated with greatly different likelihoods of future 
metastasis. For some, removing the primary tumor is often enough, whereas 
for the rest, metastasis is almost a given. A group of genes have been found 
that are consistently expressed at different levels between these subtypes, and 
which have therefore been used to develop a classification algorithm, based on 
a so-called support vector machine, which can distinguish between them. This 
approach has been found highly predictive of patient outcome72,73. As a result, 
measuring the expression of these genes can identify individuals that will need 
further surveillance. 
 Another common use case is the identification of new tumor subtypes. 
Traditional approaches have relied on histological appearance, that is, the 
microscopical structure of sections taken from tumors, and their associated 
expression of established protein biomarkers. In recent years, transcriptome-
based approaches on large cohorts have led to refinements of previous 
classifications for many tumor types, as well as the discovery of associations 
between these and specific genomic alterations15,16,74,75. For the purpose of 
subtype determination using gene expression data, unsupervised clustering on 
sample correlations is the most common approach76. The term unsupervised 
implies that no prior knowledge about tumor classifications is used to inform 
the analysis, as opposed to supervised clustering, which is used to classify 
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samples based on knowledge of true class memberships in a reference dataset. 
In the latter case, one may for instance desire establishing the diagnosis of a 
difficult case by comparing with gene expression data from diverse cancer 
types.  
 Clustering can also be used in the inverse fashion, on genes with 
respect to samples. This can determine subsets of co-expressed genes, which 
have often been found to participate in similar biological pathways77, enabling 
the discovery of new gene functions. Moreover, it is also possible to combine 
gene expression measurements with other data types in integrative clustering 
approaches, to find subgroups that share similarities also with respect to copy 
number changes and DNA methylation profiles, for instance76. 
 In addition, RNA-seq may also be used for the determination of which 
mutations are expressed in a given tumor. Related this is the prediction of 
potential antigens presented specifically by tumors, which could be targets for 
immunotherapy approaches78. In bulk tumor material, it is also possible to use 
gene expression data to dissect interactions between tumors and immune cells, 
since a given tumor is a complex aggregate of multiple cell types, including 
immune cells. These express very specific sets of genes, which can be used to 
identify their presence and cellular states. This can be accomplished with 
computational approaches that are termed deconvolution, which use reference 
expression profiles associated with specific cell types to estimate their 
proportions in the sequenced material79,80. For instance, the sequencing-based 
estimation tumor immune infiltrate composition has been found predictive of 
survival in cutaneous melanoma81,82. 
 The complexity of tumor material can also be studied with methods 
that profile expression in single cells. Recent protocols enable the sequencing 
of several thousand cells simultaneously, which can be highly informative 
about intra-tumor heterogeneity, the evolution of sub-clones and interactions 
with the microenvironment83. 
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1.7 The immune system in cancer 
The body has a natural defense against cancer development via the immune 
system, which can monitor cells that acquire extensive mutational burdens and 
grow too fast. The primary effectors are cytotoxic T-cells, which can recognize 
antigens presented on the surface of tumor cells via their T-cell receptors 
(TCR) and induce apoptosis, a cell death mechanism, in those that do not 
resemble normal cells84. T-cells that recognize antigens derived from normally 
expressed peptides tend to be depleted by the immune system in order to limit 
autoimmunity, whereas those that recognize foreign material are expanded 
into clones that target an infected or cancerous cell.  
 It is likely that this has protected us from a number of naturally 
occurring pre-cancerous cells that have arisen during our lifetimes. However, 
cancer cells can eventually become unresponsive to attacks from the immune 
system. Alternatively, the immune cells may cease to function properly, 
thereby allowing the transformed cells to spread into systemic disease84,85. 
Restoring the responsiveness of T-cells to tumors is the goal of 
immunotherapy, which shows promise as a potentially more effective way to 
treat cancer than traditional approaches78. However, tumor-immune 
interactions are complex, and critical to fully understand in order to improve 
response rates. As a result, immunogenomics has developed as a novel 
discipline, which utilizes sequencing data as a basis to dissect these relations86. 
1.7.1 Tumor antigens and T-cell recognition 
Tumor cells can betray themselves to the immune system due to fragments of 
mutated proteins being presented on their surfaces via the major 
histocompatibility complex (MHC), which is sensed by receptors on T-cells. 
Antigens derived from intracellular proteins, including any viral products that 
may be expressed, are presented on class I MHC molecules, whereas those of 
cell-external origin, such as those derived from bacteria, are preferentially 
presented on MHC class II87. Thus, class I and its associated antigens tend to 
be the most relevant in a cancer context. Although, it is also possible for MHC 
II to present endogenous peptides under some circumstances, such as via 
endocytosis of membrane components or autophagy of internal proteins88. 
MHC I activates CD8+ T-cells (those expressing the protein CD8, a TCR co-
receptor), which are the main subset responsible for anti-tumor activity, 
whereas MHC II activates CD4+ T-cells. However, the latter can also exert 
cytotoxic activity against tumor cells to some extent. MHC II is, however, not 
expressed as widely by tumor cells as MHC I, but rather tends to be utilized 
by antigen-presenting immune cells to indirectly prime responses88. For these 
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reasons, most studies in cancer so far have focused on antigens presented on 
MHC I. 
 The main MHC I genes are HLA-A, HLA-B and HLA-C. Their 
sequence composition is highly variable between individuals, which 
consequently affects the range of antigens they can present87. The high 
variability is likely due to an evolutionary need to constantly adapt to new 
pathogens. Similarly, TCR sequences are also highly variable, although to an 
even greater extent. T-cell receptors are rearranged somatically at the sequence 
level, which give rise to a broad repertoire of T-cells capable of recognizing a 
wide range of potential antigens89. To limit harmful autoimmune responses, 
T-cells are therefore subjected to a process that causes undesirable self-
recognizing cells to undergo apoptosis.  
 The process by which TCR sequences are rearranged is termed V(D)J 
recombination, deriving from the names of the composite fragments, a 
variable (J), diversity (D) and joining (J) region90. These fragments are 
combined together with a constant sequence component to form the two 
chains that are the basis for TCRs, α and β, with only the β chain including 
the D fragment, although a minority of T-cells instead present TCRs that 
utilize invariant γ and δ chains. The region at the junction of V (D) and J is 
termed complementarity-determining region 3 (CDR3) and is highly variable 
in composition, partly due to the combinatorial joining of the constituent 
fragments, but also a result of the possibility to add or delete nucleotides at 
their joining ends91. This region is the most critical for antigen recognition.  
 It is currently possible to determine the sequence composition of 
TCRs at a single-cell level, as a result of recent technological advancements. 
Since TCR composition essentially tags unique T-cell clones, this makes it 
possible to study clonal T-cell dynamics in tumor immune infiltrates. Paired 
with transcriptome sequencing, this further enables determination of the 
respective activation states of each clone, aiding in the discovery of subsets that 
have become activated as a result of tumor antigen-derived stimulation92,93. 
 Antigens derived from mutated proteins, which are exclusively 
presented by the tumors, can offer a way to specifically target the latter, while 
sparing normal cells78. Such “neoantigens” can be detected by computational 
methods from sequencing data (Fig. 7). The steps for detection involve 
establishing the somatic mutations in the tumor, determining the genotypes 
of the HLA genes in an individual, assessing which mutations are expressed 
and predicting the binding affinity of the mutated protein fragments to each 
HLA complex86. The peptides recognized by MHC class I are usually around 
9 amino acids long and their composition determines the likelihood of 
binding94. Different methods exist for predicting binding affinity. A 
commonly used algorithm utilizes an artificial neural network model trained 
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on features of peptides known to be presented by specific HLA molecules94. 
However, current methods still tend to suffer from high rates of false 
positives95. Besides inaccuracy in binding predictions, this is partly also due to 
other complex factors influencing presentation, including whether or not the 
cellular protein degradation machinery generates the predicted peptides, and 
whether the cell can successfully transport them to MHC. 
 In addition to neoantigens, tumors can also be targeted with some 
specificity by the immune system if they express genes that are not normally 
expressed by most cell types, such a cancer germline antigens (also known as 
cancer testis antigens), which are normally restricted to germline cells and 
trophoblasts93. Frequently, it is also found that tumors contain infiltrating T-
cells that recognize other highly expressed lineage-specific markers, such those 
involved in melanogenesis in melanoma96. However, therapies activating a 
response towards such antigens may induce harmful autoimmune responses, 
as they are also expressed in a fraction of normal cells96. 
1.7.2 Immune evasion 
Malignant cells that form tumors and spread are able to do so because they 
have developed ways to avoid an effective immune response. This can occur 
via a number of means (Table 2). The immune system has a number of 
checkpoints in place to prevent persistent inflammation and autoimmune 
problems. One type of checkpoint consists of certain of receptors that can be 
expressed on the surface of T-cells, which occurs after prolonged antigen 
stimulation97. When bound to their respective ligands, these T-cells refrain 
from killing their targets. Checkpoint ligands can be expressed by other 
immune cells in the tumor microenvironment, but in some cases also by the 
cancer cells themselves. As this begins to occur, T-cells start to enter a state 
known as exhaustion, limiting their capacity. 
 In addition, suppression of immunity also occurs as a result of a the 
activity of a specific class of T-cells known as regulatory T-cells, which are 
Filter by expression Determine short peptidescontaining mutation
Predict binding
(machine learning)
DNA-seq
RNA-seq
Mutation
calling
Mutation
calling
Determine HLA class I 
genotypes
Figure 7. Workflow for computationally predicting neoantigens that may be 
presented by tumors. After determining expressed peptides containing a given 
mutation, these are screened for estimated binding affinity to HLA class I molecules, 
determined from genome or RNA sequencing of the patient. A current state-of-the-
art method to predict binding uses an artificial neural network model for this purpose. 
Biological validation experiments are required to confirm antigen presentation. 
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often found highly represented near the tumors98. Other suppressive cell types 
can also contribute to a failed anti-tumor response, such as M2 macrophages 
and myeloid-derived suppressor cells. Transition of macrophages towards the 
suppressive M2 state can additionally be promoted by lactate production from 
cancer cells. Lactate is a byproduct of glycolysis, which most cancer cells are 
highly reliant on98. 
 Furthermore, cancer cells can downregulate or mutate genes used for 
antigen presentation (HLA-A, HLA-B and HLA-C), genes involved in the 
transport of peptides to MHC (TAP1), or β2 microglobulin (B2M), which is 
a critical component of functional MHC I85. As a result, T-cells are no longer 
able to identify the cancer cells as unusual. Normally, NK cells can recognize 
loss of HLA expression and target the tumor cells85. However, tumors can also 
express molecules inhibiting NK cell activity, including both checkpoint 
ligands such as PD-L1 and soluble ligands that bind to the receptors used by 
NK cells to identify cells that are missing antigen presentation, essentially 
diverting their attention99. 
 Moreover, tumors can also promote the exclusion of immune cells 
from their local environment. This can occur through the expression of certain 
chemokines, molecules influencing cell migration, which act to keep subsets 
of cytotoxic immune cells from entering98,100. The same chemokines, some of 
Intrinsic Extrinsic 
• Expression of immune checkpoint 
ligands (for instance PD-L1). 
• T-cell exhaustion, anergy or 
senescence. 
• Resistance to apoptosis, which 
prevents T-cells from inducing cancer 
cell death. 
• Regulatory T-cell presence, which 
suppresses the activity of cytotoxic T-
cells. 
• Defective antigen presentation, which 
can occur due to downregulation or 
mutation of critical genes, for instance 
B2M, TAP1 and HLA-A, -B and -C. 
• Expression of checkpoint ligands by 
other immune cell types in the tumor 
microenvironment, including myeloid-
derived suppressor cells, tumor-
associated macrophages and 
dendritic cells. 
• Cancer cell expression of chemokines 
contributing to exclusion of cytotoxic 
T-cells from the tumor 
microenvironment. 
• Expression of chemokines 
contributing to exclusion of cytotoxic 
T-cells by other cells in the tumor 
microenvironment. 
• Production of lactate, which can 
induce transition of tumor-associated 
macrophages towards the 
suppressive M2 phenotype. 
• Physical exclusion of immune cells 
from the tumor environment via, for 
instance, a thick extracellular matrix 
created by cancer-associated 
fibroblasts. 
Table 2. Common immune evasion mechanisms. Intrinsic refers to mechanisms 
mediated by the cancer cells themselves, whereas extrinsic refers to factors of the 
tumor microenvironment. Most of these aspects are possible to study using either 
RNA or DNA sequencing data. 
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which can also be expressed by other cells in the microenvironment, may, 
however, still allow for the entrance of immune suppressive cell types, 
including regulatory T-cells. Physical exclusion may also occur due to 
development of an impenetrable extracellular matrix, which cancer-associated 
fibroblasts can contribute to98. 
1.7.3 Immunotherapy 
Knowledge of the mechanisms whereby T-cells eventually fail to eradicate 
tumors has led to the development of therapies aimed at reinvigorating their 
activity. Among the most successful of current immunotherapies are those that 
target immune checkpoint receptors or ligands, most commonly PD-1, PD-
L1 or CTLA-4, through the use of inhibitory antibodies78. A number of cancer 
types can display great responses to these, most prominently cutaneous 
melanoma, but far from every patient receives any benefit. On the pessimistic 
side of the spectrum are cancers where these treatments almost completely lack 
effect, for instance uveal melanoma101. An increased understanding of the 
operative immune evasion mechanisms that determine outcome will be 
required to design more effective options for these patients. 
 Another immunotherapy approach utilizes chimeric antigen receptor 
T-cells (CAR-T), where T-cells are modified to express TCRs that recognize 
tumor specific antigens78. With this option, it is of importance to ensure that 
other cells in the body are not targeted, which might be the case if the antigens 
are not exclusive to the tumors. It also remains a risk that the TCRs used may 
cross-react with unknown antigens presented by normal cells78. Potentially, 
neoantigens could be useful as targets with CAR-T, although most studies 
have focused on other ones derived from genes expressed with specificity in 
tumors102. A third class of immunotherapies are vaccine-based. With these, 
antigenic peptides themselves are used to prime the immune system, which 
can be accomplished by a variety of means. For instance, dendritic cells (DCs), 
which present antigens to T-cells, can be loaded with such peptides and 
transferred to patients to prime subsequent responses. It is also possible to 
deliver tumor-specific peptides themselves into the patient, aimed at achieving 
a similar indirect effect. Responses with these therapies have not been as 
promising as for checkpoint inhibition, however. Although, it is possible that 
combinations of them may improve outcomes103. 
 Factors known to associate with the success of immunotherapies 
include, among others, total mutational load, indirectly implying neoantigen 
load; the proportion of CD8+ T-cells infiltrating the tumor, the expression of 
immune checkpoint genes, presence of genomic alterations affecting antigen 
presentation components, as well as expression signatures associated with 
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immune cell exhaustion or exclusion28,81. All of these factors are possible to 
study to some extent with genome and transcriptome sequencing93. 
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2 Aims 
This thesis aims to investigate the range of answers that can be derived from 
the genomes and transcriptional material of tumor cells, to questions 
concerning cancer development. The included papers focus on a range of 
topics in cancer genomics, from tumor classification to profiling of driver 
events and immune landscapes. Material from large public resources of tumor 
sequencing data is utilized, as well as patient material from Sahlgrenska 
University Hospital. The focus of each paper is as follows: 
 
I Determination of the origin of a metastatic cancer of 
unknown primary based on DNA and RNA sequencing. 
 
II Development of a method to prioritize genes of interest in 
focal copy number changes based on integration with gene 
expression data. 
 
III In-depth molecular characterization of uveal melanoma 
metastases, concerning driver mutations, mutational 
spectrum, genes of interest in recurrent broad copy number 
changes and the phenotypes of tumor-infiltrating T-cells. 
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3 Results and discussion 
3.1 Paper I 
Cancer of unknown primary (CUP) is the diagnosis arrived at when the 
patient presents with metastatic disease but it is not possible to determine the 
primary cancer type or its site of origin. Knowledge of this is important for 
deciding an appropriate and effective treatment. As a result, these patients are 
most commonly treated with general cytotoxic chemotherapies, which tend to 
be unsuccessful and can have a wide range of undesirable side effects. 
Naturally, mortality within this group of patients is very high104. However, the 
tumors may have specific driver mutations for which targeted drugs could be 
available. This alone would justify some level of genomic profiling. But even 
so, these drugs may not work equally well in all cancer types driven by the 
same mutation105, and some drugs have only been approved for use in specific 
cancers. Therefore, tumor classification is also a priority. 
 In this study, we encountered a patient that had been misdiagnosed 
three times previously. The tumor was originally thought to be a lung cancer 
with an oncogenic fusion involving ALK, but later re-evaluation discovered 
this to be a false positive finding. Due to prominent neuroendocrine 
characteristics, the diagnosis was changed to a neuroendocrine lung cancer. A 
third re-evaluation confirmed the neuroendocrine-like phenotype, but favored 
the diagnosis of paraganglioma, albeit an unusual case with a BRAFV600E 
mutation. This mutation is very common in melanoma12. However, all 
decisive melanoma markers examined by immunohistochemistry on both a 
brain and subcutaneous metastasis were negative. Fortunately, this mutation 
is possible to treat with a BRAF inhibitor, which was also done here with 
temporary success, although resistance eventually developed. At this point in 
time, whole genome and transcriptome sequencing was performed on both of 
the metastases. 
3.1.1 Establishing the origin of a metastasis with sequencing 
data 
Genomic profiling uncovered two potential resistance mutations in MAP2K1 
and a homozygous focal deletion of the tumor suppressor CDKN2A. 
Transcriptome analysis confirmed high expression of neuroendocrine and 
neural crest markers. No known oncogenic fusions were discovered, of 
relevance since some paragangliomas have been found positive for fusions 
involving MAML3106.  
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 Following this, an analysis of the mutational spectrum of the tumor, 
considering synonymous and non-synonymous exonic variants, revealed a 
prominent mutational signature associated with UV-induced damage (Fig. 
8a), questioning the previous diagnosis. The contribution of this signature to 
the overall mutational load was estimated to 80%. The pattern was identical 
in both the skin and brain metastasis from the patient. This precluded a 
primary origin in the lung region. A transcriptomic comparison to gene 
expression profiles of over 9500 TCGA tumors from 32 different cancer types 
showed strong matches to cutaneous melanoma (CM, Fig 8b). As a result we 
could firmly establish the diagnosis for this patient. 
 The strong expression of neural markers was likely related to the fact 
that melanocytes derive from neural crest or, alternatively, Schwann cell 
precursors107. This, and the lack of expression for decisive melanocyte markers 
may be explained by either a dedifferentiation towards an earlier 
developmental state of the cell or transformation of a precursor present in the 
skin. 
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Figure 8. a) Mutational spectrum, as measued by overall trinucleotide substitution 
frequencies in a subcutaneous and brain metastasis of the patient (compare with 
Fig. 6). b) Gene expression data from both metastases were compared with 9583 
tumors from 32 cancer types available from TCGA. t-SNE analyses grouped both 
samples with cutaneous melanomas. The same cancer type was also predicted 
using an independent 6-nearest nighbor classification based on Spearman 
correlations. 
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3.1.2 The utility of DNA and RNA-seq for cancers of unknown 
primary  
These findings demonstrate that DNA and RNA-seq analysis can be highly 
useful in the study of cancers that are difficult to categorize with traditional 
methods. A novel aspect here is that the overall mutational spectrum in the 
tumor can reveal important clues, since a signature of carcinogens only 
expected to be encountered in very specific parts of the body can exclude a 
range of alternatives. In fact, we found that the UV signature could even 
discriminate between TCGA head and neck squamous cell carcinomas that 
arise on the lip from those that arise elsewhere in the oral region. Furthermore, 
analysis of the TCGA lung squamous cell carcinoma cohort also revealed three 
samples with prominent UV signatures, arguing that they were actually 
metastases from elsewhere. Although not all known mutational signatures are 
likely to be equally informative, the analysis is relatively straightforward if 
sequencing data is already available. The potential discovery of therapeutically 
actionable driver mutations, copy number changes and fusion genes is already 
a strong argument for performing genome and transcriptome sequencing. The 
latter can also be used for mutation discovery and, when paired with DNA-
seq, further allow the exclusion of false positive variants. Standardized analysis 
pipelines are possible to implement and can potentially yield important 
information in a short time period. 
 Furthermore, recent global sequencing projects, i.e. TCGA, have 
made available massive datasets for numerous cancer types, which are possible 
to use as a reference in transcriptomic comparisons. Such analyses can 
evidently uncover details missed by traditional immunohistochemical staining 
approaches. We evaluated this method of classification using leave-one-out 
cross-validation on each tumor in TCGA and found accuracy to be 95%, with 
84% accuracy on an independent dataset. 
 The latter was mainly composed of uveal melanoma (UM) metastases 
and CM patient-derived xenograft (PDX) models, which may be argued to be 
somewhat limited. The lower performance on this dataset, however, 
highlighted some important flaws with the approach that one should be 
mindful of. Namely, the purities of metastases are likely to influence the 
results, since the presence of hepatocytes in a fraction of UM liver metastases 
led to misclassification of some as liver hepatocellular carcinoma. In addition, 
the TCGA cross-validation also showed that tumors deriving from similar cell 
types had higher misclassification rates. Yet another issue to be aware of is that 
the TCGA data is not fully comprehensive, in that it lacks both some common 
cancer types, such as cutaneous squamous and basal cell carcinoma, as well as 
a number of rare cancers. The latter may be alleviated with time as future 
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sequencing studies contribute more data. A workaround for purity issues could 
be to develop an integrative classification approach that also considers 
mutations and copy number profiles, since these also possess some amount of 
distinctive qualities.  
 For the application of this framework on CUP, additional factors need 
to be taken into account. Material from such tumors presently tends to be 
stored under formalin-fixed paraffin-embedded (FFPE) conditions, which is 
associated with artifactual base substitutions, as well as RNA degradation108. 
Epigenetic assays have been described that may work better for such 
samples109, although the two methods remain to be compared. Epigenetic 
profiling is also likely to be cheaper. Ideally, however, DNA and RNA-seq can 
provide additional information that could be highly useful, such as the 
detection of targetable fusion oncogenes, mutations, presence of viruses and 
immunogenomic profiling (Fig. 9). This could potentially justify the 
additional costs associated with sequencing. Naturally, one could also argue 
for improved storage conditions of CUP samples going forward. 
 In all, this study highlighted the fact that much more can likely be 
done for the group of patients whose tumors are currently classified as 
indeterminable and, in most cases, largely untreatable. We can most likely 
assign this group to more effective options by comprehensively profiling their 
disease molecularly, however one may decide to do this in the most cost-
effective way. 
Tumor sample
Exome sequencing RNA sequencing
k-nearest
neighbors
Mutation calling
Mutational signature
analysis
HLA analysis
t-SNE
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Copy number
analysis Classification Viral read mapping
Fusion gene
detection
Figure 9. Illustration of information that can be extracted from RNA and exome 
sequencing, which may aid in tumor classification and treatment selection. PBMC: 
peripheral blood mononuclear cells, commonly used as a control sample of normal 
cells. 
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3.2 Paper II 
Genomic instability can cause the accidental duplication or loss of genetic 
material. Such copy number changes can activate oncogenes or inactivate 
tumor suppressors. If these events provide a selective advantage, those cells will 
expand in numbers relative to those that lack them. It is commonly found that 
tumors from multiple patients have somatic copy number changes affecting 
the same genomic regions. This implies that those changes may have 
contributed to the formation and survival of the cancer. Studying these 
recurrent events can give clues about potential driver genes, which may suggest 
new therapeutic targets11. 
 However, the affected regions in a given tumor often span many genes, 
making it challenging to identify the ones that are most relevant. Therefore, 
one typically searches for regions of minimal overlap between recurrent 
changes, which indicate genes that are altered in the majority of tumors. 
However, random inconsequential events may also overlap such a locus, 
shifting the minimally overlapping region away from the actual driver gene, 
and additionally, such regions may still contain multiple candidates43. 
3.2.1 Recurrent focal copy number and gene expression 
changes 
The primary means by which copy number changes can drive cancer is via 
changes in transcriptional output. However, not all genes that experience copy 
number gains or losses are markedly affected in terms of expression. Therefore, 
to further limit the search space for genes of interest, one may integrate the 
information obtained from DNA with that of RNA-seq. The natural approach 
for this would be to assess correlations between copy number and expression 
for each gene. This has a number of weaknesses, however. On one hand, the 
effects may not always conform to the types of trends assessed by correlation 
methods. On the other hand, larger simultaneous changes in copy number 
and expression, or smaller amplitude gains with large effects, would be 
expected to provide stronger evidence than others, but these instances will not 
be rewarded to any additional extent in the calculation of a correlation 
coefficient. Furthermore, these approaches do not take into account the fact 
that more size-limited alterations are more informative about the relevance of 
each gene in the overall region that is altered across tumors. 
 Here, we developed a screening tool that instead uses an approach 
similar to covariance, where stronger dosage effects will have a greater relative 
contribution to the final score of a gene. As a basis for this calculation, changes 
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in gene expression or copy number relative to the median values in samples 
diploid at a given genomic position is used. In addition, the scoring system 
prioritizes focal events by subtracting broad changes from the copy number 
amplitudes in each sample prior the calculation. The hypothesis is that the 
best-ranked genes in each region are more likely to be driver genes than lesser-
ranked ones. The method can be used either on gene-level or on continuous 
intervals across the genome (Fig. 10), facilitating analysis also of unknown 
transcripts. To automatically find regions across the genome with clustered 
high scores and select the strongest candidates, a peak detection algorithm is 
then used. 
3.2.2 Peak detection 
Detecting the type of genomic peaks resulting from these scores is a challenge, 
since the difference between a peak and a sub-peak is not easy to define in a 
way that consistently works across the genome and across different cancer 
types. It is also dependent on the desired level of sensitivity and specificity, 
since one can theoretically call each individual score a peak, and miss no genes, 
but be unable to interpret the results. Conversely, one may also call an entire 
chromosome a peak and retrieve only the highest ranked gene within it as a 
candidate. Most evaluated algorithms for peak detection, mainly developed 
for signal processing, were also found to rely on assumptions that all peaks 
conform to certain statistical distributions, which is not the case here, since 
genomic elements are unevenly distributed and genes often have uncorrelated 
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Figure 10. Illustration of scores calculated by the developed method (FocalScan) in 
regions of recurrent copy number change, based on breast cancer data from TCGA. 
Upper panel: summed log2 ratios of copy number changes relative to a diploid 
chromosome, contrasted with the corresponding profile for copy number changes 
where broad events have been subtracted. The respective scores calculated for 
each gene by integrating these changes with alterations in gene expression are 
shown below. Lower panel: zoomed view of the region surrounding the gene 
CCND1, which was the most recurrent amplification event on this chromosome. 
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levels of transcription. These methods also required a large number of user-
defined parameters. Settings that worked well on one cancer cohort often 
failed on another. 
 The proposed solution to this problem works by first considering each 
gene that has a higher score than its two neighbors as a peak. Then, a higher 
level of peaks is defined as those peaks from the previous level that are greater 
than their two neighbors. This process repeats until only one gene on the entire 
chromosome is considered a peak. Depending on the desired degree of 
specificity, one can then select an intermediate level of choice to obtain a 
reasonable number of peaks across the genome (Fig. 11). The peaks formed 
this way are independent of the distances between genes and between sub-
peaks, and the method does not assume any specific statistical distribution. 
The only parameter needed is the desired choice of specificity, which can be 
specified as a percentage relative to the total number of levels generated. The 
latter also made it possible to run the algorithm with comparable performance 
on different cohorts using the same setting. 
 The combined use of a scoring system that weighs recurrence, focality 
and coordinated changes in copy number and gene expression together with 
this peak detection approach led the method to outperform other similar 
methods designed for ranking potential driver candidates, as defined according 
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Figure 11. Peak detection performed on scores derived from TCGA breast cancers. 
Detection can be performed on multiple levels of granularity (specified as a 
percentage), two of which are shown here. A higher value gives fewer peaks, but 
may miss genes of interest that form peaks in close regions, whereas a lower value 
will nominate more candidates by dissecting larger peaks into sub-peaks, but this 
may also yield noisier results.  
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to enrichment of known cancer driver genes within the ranked list of putative 
targets generated. 
3.2.3 Recurrently altered unknown transcripts 
Recurrent focal copy number changes can sometimes be found in regions 
where no known genes exist, which are also relevant to consider. This was not 
an option with other current approaches. Therefore, we added the ability to 
calculate scores for continuous small sections of the genome, thus making the 
method optionally independent of a reference genome annotation. 
 Fig. 12 shows one such unknown transcript nominated by the method 
as recurrently focally amplified and upregulated in TCGA breast cancers. This 
occurred in an intronic region of PVT1, but did not correspond to any 
alternative exon of this gene. PVT1 is adjacent to the oncogene MYC, but the 
nominated transcript received a higher score than either. Later studies have 
shown that the PVT1 locus contains a cluster of enhancers, some of which can 
control MYC expression110. One such enhancer region, as determined with a 
CRISPR interference screen, corresponded precisely to the location of this 
peak110. The transcript produced here is likely an enhancer RNA (eRNA), 
which is a class of non-coding transcripts produced at enhancers that have 
been found correlated with their activity111. Recurrent focal amplifications of 
enhancers that lead to MYC overexpression have recently been found in lung 
adenocarcinoma, endometrial carcinoma, T-cell acute lymphoblastic leukemia 
and neuroblastoma112-114. This illustrates that the method is capable of 
nominating candidates for further experimental studies also in regions without 
known genes.  
 A weakness of the approach is that these ranked lists are only indicative 
of the relative strengths of association of each genomic element with factors 
that relate to selection, but are not direct statistical tests for selection as such. 
Thus, the output is not a statement that a given element is under selection, 
but merely an aid in the prioritization of genes within regions of recurrent 
copy number changes. There does not currently seem to exist any integrative 
method that statistically assesses positive selection. Most likely, this is due to 
the difficulty in defining a null model for what constitutes RNA levels that are 
not under selection. To achieve a more statistically based assessment of 
possible selection using the above described method, one may focus the 
analysis on regions where copy number aberrations have been determined to 
occur more frequently than expected by chance, for which there are existing 
methods available to assess43.  
 In addition, the method benefits greatly from a large number of 
samples being used, preferably in the hundreds, which is available for TCGA 
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data, but typically not with in-house generated datasets. From a usability 
standpoint, the method could also be improved by outputting a merged list of 
candidates across different peak calling levels to enable a comparison of all top 
candidates that may be nominated with different settings in a given region, 
since some true driver genes present in what could be considered sub-peaks 
may otherwise be missed. A further limitation is the concentration on focal 
events. Several cancer types display frequent, if not exclusively, broad 
chromosome arm-level changes. Currently, few, if any, studies have been made 
that properly investigate candidates within these, simply due to the vast 
number of genes they contain and the absence of any minimally overlapping 
region to guide the analysis. We attempt to address this issue to some extent 
in Paper III. 
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Figure 12. Non gene-centric scores in a focally amplified 
region, followed by peak detection, nominates an unknown 
transcript intronic to PVT1. The transcript coincides with 
histone 3 lysine 27 acetylation and DNase clusters 
indicative of an active enhancer. 
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3.3 Paper III 
Uveal melanoma (UM) is a rare eye cancer affecting the choroid or ciliary 
body, or less commonly the iris, which together constitute the uvea. However, 
it is also the most common form of eye cancer115. The biology of UM is 
distinct from cutaneous melanoma (CM), with mostly unknown underlying 
causes, as well as driven by a different set of oncogenes and tumor 
suppressors12,16,115. Approximately 50% of patients develop metastases, mainly 
to the liver, which is closely tied to the presence of inactivating genomic 
aberrations in the tumor suppressor BAP1115. Treatment of primary UM most 
commonly involves enucleation of the affected eye or destruction of the tumor 
with radiation116. In the metastatic state, however, no effective treatments 
exist. While immunotherapy has been highly successful in CM, little to no 
responses are seen in UM. Current targeted drugs and general cytotoxic 
therapies also lack efficacy115,116. 
 To gain additional insights into the genomic characteristics of 
metastatic UM, we have examined the whole genomes and transcriptomes of 
metastases from 24 patients. We additionally profiled tumor-infiltrating T-
cells at the single-cell level from eight patients with respect to their 
transcriptomes and T-cell receptors (TCRs), to better understand their 
phenotypes and how they may relate to the failure of immunotherapy. 
3.3.1 BAP1 loss is frequent and drives transcriptomic changes 
towards a metastatic phenotype  
We discovered mutations in the established driver genes GNAQ and GNA11 
to be present in approximately half of the samples each, in addition to less 
frequent mutations of SF3B1, CYSLTR2 and PLCB4. Furthermore, we found 
inactivating mutations in BAP1 in 23/24 samples (96%), consistent with the 
well-known association of BAP1 loss-of-function and metastasis. In the vast 
majority of cases, this was also coupled with loss of one copy of chromosome 
3 (monosomy 3), where BAP1 is located, thus contributing to gene 
dysfunction via LOH. These events are known to frequently co-occur in poor-
prognosis tumors116.  
 Some of the mutations in this gene also affected splice sites. The pairs 
of nucleotides adjacent to each exon are considered the ones most critical to 
splicing117. Two tumors had base substitutions affecting these regions, and 
RNA-seq from the same tumors displayed elevated intron retention around 
the affected exons. The result of this can be transcripts that are unable to 
become successfully translated into functional proteins26. In another sample, 
an intronic mutation was found directly adjacent to a part of an intron that 
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was retained, but distant from any splice site. The sequence motif at this 
position also suggested the creation of a new intronic splice site. Common 
variant filtering practices frequently disregard intronic non-splice site 
mutations, but this finding would serve as an example for further considering 
them. This may be especially important if a single gene inactivation is 
predictive of future metastasis, as is the case in UM. 
 BAP1 has also been discovered as a tumor suppressor in a number of 
other cancer types, including renal cell carcinoma and mesothelioma118. 
Several mechanisms for its anti-tumor activity have been proposed, including, 
but not limited to, participation in the DNA repair machinery, cell cycle and 
metabolic regulation, apoptosis, ferroptosis (a cell death program induced by 
oxidative stress) and regulation of differentiation119-127. Given the variety of 
mechanisms proposed in different cancer types, it is possible that the role of 
BAP1 is context specific. This is likely, since BAP1 is a histone deubiquitinase, 
which enables potential epigenetic regulation of a large number of genes128. 
The set of genes susceptible to regulation is likely to vary between cell types 
due to differences in underlying epigenetics states. Furthermore, it has been 
found that small interfering RNA (siRNA)-mediated knock-down of BAP1 in 
UM cell lines leads to downregulation of melanocyte lineage markers, 
suggesting dedifferentiation, which could be counteracted by inhibiting the 
histone deacetylase HDAC1, which also implies an epigenetic mechanism122. 
 To gain further insights, we reintroduced a functional copy of the 
BAP1 gene, using a viral vector, into a tumor-derived cell line possessing a 
dysfunctional variant due to a homozygous frameshift deletion. We then 
compared gene expression in this tumor to cells transfected with an empty 
vector control. A large number of genes were significantly differentially 
expressed. However, we also noted that 7/12 genes included in an expression-
based clinical prognostic test that accurately discriminates between the two 
major UM subtypes were among these72,73. These two subtypes are commonly 
referred to as class I and II, respectively. These genes were all altered in the 
same directions prescribed by the test as indicating a good-prognosis subtype 
upon BAP1 reintroduction. We examined this further by testing for the 
enrichment of two larger sets of genes previously identified as differentially 
expressed between these subtypes129. This revealed a strong enrichment for 
class I genes among those upregulated upon reintroduction, and equally strong 
enrichment for class II genes among those downregulated. This suggests a 
broad transcriptomic shift towards a better-prognosis phenotype, or 
conversely that loss drives cells towards the metastatic phenotype. 
Furthermore, it also implies that the factors that determine the two major UM 
subtypes are regulated by BAP1. The broad response, comprising a varied set 
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of cellular pathways, would also be compatible with epigenetically mediated 
regulation. 
3.3.2 Evidence of UV-induced damage in an iris melanoma 
The reasons UM develops are still unknown, but a number of risk factors have 
been identified. These include light eye color, Caucasian ethnicity, 
geographical latitude and welding130. While sun exposure may be easily 
suspected based on some of these, and due to its role in CM, it has never been 
conclusively shown that this is a true risk factor. Some of the known risk 
factors could also have an origin in a genetic predisposition common to 
Caucasians. Adding to this is the results of several UM genomic studies that 
have assessed the mutational spectrum of the tumors, and found no indication 
of the well-known UV signature (Fig. 6)131,132. This suggests that UV-induced 
damage is unlikely to play a major role in the development of UM. 
 We investigated the contribution of established mutational signatures 
to each tumor in this cohort, and included four simultaneously sequenced 
CMs for reference. When clustering all tumors on the estimated relative 
contributions of each signature, we found that UMs possessed distinct profiles 
compared to CM. The main contributing signatures in UM were associated 
with aging and certain DNA repair deficiencies, but one was also found that 
is not currently assigned any known underlying mutational process. CMs, on 
the other hand, were mainly characterized by contributions from the UV-
associated signature, as expected. There was, however, one exceptional UM 
that clustered distinctly together with the CMs and which displayed a 
prominent contribution from the UV signature, which has not before been 
observed for UM tumors. By additional analyses, including a transcriptomic 
classification similarly to Paper I, we were able to exclude the possibility of a 
sample mix-up or misdiagnosis. The likely explanation for this case is that the 
tumor was an exceedingly rare specimen that developed in the iris, which is 
estimated to only occur in about 5% of cases130. Arguably, the iris is more 
exposed to UV light than the choroid or ciliary body of the uvea. This provides 
DNA-level evidence for the involvement of UV damage, but suggests that it 
may only be a potential risk factor in iris melanomas.  
3.3.3 Copy number and gene expression changes associated 
with metastasis 
UM predominantly harbors arm-level copy number changes, with no 
oncogenes or tumor suppressors described as targeted by recurrent focal 
changes in recent large-scale sequencing studies, besides BAP116,116,132. 
However, several of these broad changes are highly recurrent and some, such 
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as gain of 8q and loss of 6q, besides loss of 3, are also significantly associated 
with metastasis116,132-135. Consistent with this, we also found that gains of 8q 
and losses of 6q were significantly overrepresented in the metastasis cohort 
compared to TCGA tumors, which are all primary. In addition, we also found 
17p loss and 5p gain overrepresented. Notably, we also discovered focal 
deletions affecting the tumor suppressor CDKN2A in two tumors, which have 
not been described in other recent UM genomics studies16,131,132,136. Since most 
studies have focused on primary tumors, the occurrences of this event here 
could suggest that they are late events in the evolution of the tumors. One may 
speculate that loss of CDKN2A could potentially influence metastatic 
progression. 
 The presence of clinically prognostic arm-level copy number changes 
motivated us to search for genes consistently altered in expression within these, 
and prioritize among them on basis of protein-interaction data to find genes 
that may exert broader effects on cellular phenotypes when perturbed. The 
latter would be expected for any gene putatively conferring a selective 
advantage to the tumor cell. It should be noted here, however, that copy 
number changes might also inactivate tumor suppressors through LOH 
combined with a mutation, or potentially result in fusion genes at their 
breakpoints. However, no significantly recurrent mutations or fusions have 
been observed for genes in the regions subjected to these aberrations, leaving 
expression changes as the most probable mechanism for mediating an 
advantage. 
 Based on these assumptions, we screened for genes that had consistent 
associations between expression and copy number in both our own cohort and 
TCGA UMs. We then ranked them based on their numbers of interacting 
partners in a curated protein-protein interaction database137, and binary 
membership in pathways previously identified as perturbed overall in TCGA 
UMs16,138. The former database would constitute pre-existing evidence 
suggesting a potential for impact. Use of the latter method relies on the a 
posteriori argument that pathways objectively altered by genomic events in UM 
contain these genes, and therefore members of these pathways would be more 
likely to influence mechanisms of relevance than unrelated genes, even though 
the latter may still have large theoretical interactomes. Lastly, we also 
considered univariate expression associations with survival in the TCGA 
cohort, but only used this to further rank within the list already established 
from the previous analyses. The motivation for not considering survival data 
as stronger evidence was that it is easily confounded by numerous genomic 
and clinical parameters, which are difficult to adequately adjust for, hence also 
the choice of univariate survival statistics. 
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 By thus ranking genes based on these evidence classes, a number of 
candidates emerged, which by definition were consistently associated with the 
underlying copy number events and possessed a potential for a wider 
phenotypic impact. Examining the top candidates, we found genes in regions 
of loss to be enriched for apoptosis pathways, whereas genes in gained regions 
were enriched for hemostasis, integrin signaling and a few other pathways that 
have some relation to GNAQ/GNA11 activity. Furthermore, we noted a 
significant overrepresentation for genes upregulated in class II tumors129 in 
regions of gain and class II downregulated genes in regions of loss, indirectly 
validating the associations in a third independent dataset. Altogether, this 
suggests that the recurrent broad copy number changes in UM are unlikely to 
be functionally inert, and argues against the notion that these events may only 
influence tumor phenotypes via general side effects of aneuploidy. 
 Among the first-ranked genes for each region were some of particular 
interest. For instance, CASP9, which initiates the apoptotic cascade139, 
experienced recurrent loss and downregulation on chromosome 1p. The 
highly prevalent gain of 8q was associated with persistent upregulation of 
PTK2 (focal adhesion kinase), which suppresses an apoptotic program 
initiated as cells lose contact with their surroundings (anoikis), thus enabling 
anchorage independent growth, a hallmark of metastasis140,141. Consequently, 
PTK2 overexpression has been associated with metastasis and worse survival 
in a number of cancer types140. Such a role would also be consistent with our 
observation that each tumor in the metastasis cohort had 8q gains, and with 
previous studies establishing their association with UM metastasis. 
Furthermore, CDH1 (E-cadherin) underwent loss and downregulation on 
16q; a gene that is important in contact inhibition, a mechanism that 
suppresses proliferation and migration when the cell is in contact with other 
cells142. Naturally, loss of CDH1 has also been associated with metastasis in a 
several cancers142. Given that metastatic UM currently has no effective targeted 
treatment, further functional studies of the above genes may be of 
interest143,144. 
3.3.4 Phenotypes of tumor-infiltrating T-cells 
The high failure rate for immunotherapy in UM motivated us to profile the 
phenotypes of tumor-infiltrating T-cells, the primary immune cells that 
mediate anti-tumor activity. To do so, we performed paired transcriptome and 
TCR sequencing of close to 30000 individual T-cells infiltrating the tumors 
of eight patients. By transcriptomically classifying immune cell 
subpopulations using reference gene sets derived from pure cell types, we 
discovered heterogeneous immune cell communities. One sample in particular 
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hardly contained any infiltrating cytotoxic CD8+ T-cells, but was rather 
dominated by CD4+ cells, some of which were regulatory T-cells that have a 
suppressive role. This tumor also had the lowest expression of the MHC class 
I genes, offering a potential explanation for the low level of infiltrating CD8+ 
cells, since the former are responsible for attracting the latter to their targets. 
 A theme that recurred across all samples was widespread expression of 
inhibitory receptors on T-cells. Notably, expression of the molecules LAG3, 
TIM-3 and TIGIT was more prominent than PD-1 or CTLA-4, against which 
current checkpoint blockade immunotherapies are directed. This additionally 
indicated that the T-cells were in an exhausted state. In support of this, we 
also found lower levels of cell cycle gene signature expression in some of the 
samples with the highest fractions of T-cells expressing these receptors. 
 However, the presence of certain exhaustion markers is also indicative 
of past antigen recognition and tumor-reactivity. Adding to this were greater 
levels of clonal expansion within tumors with more exhausted communities, 
as inferred by studying subsets of cells with identical TCRs. While we did not 
discover any solid evidence suggesting the involvement of neoantigens in such 
tumor recognition, we were able to determine binding to common melanoma 
antigens by T-cells from four tumors, using functional assays. 
 Thus, we could conclude that UM metastases do harbor tumor-
recognizing infiltrating T-cells, but that they tend to have highly exhausted 
phenotypes. It is also possible that PD-1 and CTLA-4-directed 
immunotherapies fail due to expression of the additional checkpoint receptors 
LAG3, TIM-3 and TIGIT.  
 In summary, this study has offered insights into the consequences of 
BAP1 loss, highlighted a potential new risk factor for UM development, 
nominated genes of interest in recurrent broad copy number aberrations and 
provided a characterization of the landscape of infiltrating T-cells in metastatic 
tumors. This knowledge may open up new opportunities for research on 
potential therapeutic targets and alternative strategies for immunotherapy in 
UM. 
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4 Conclusions and future perspectives 
Ultimately, cancer is an evolutionary issue. Cancer arises because a few cells in 
our body develop a selective advantage due to genomic changes. These then 
carry out their own egotistical lives without care for whether or not the 
remaining cells in the organism agree with it. They spread and colonize 
anywhere they can, eventually causing the dysfunction of critical organs. 
Surgically removing the tumors they form eventually becomes fruitless, since 
they may be deeply infiltrating vital sites that cannot be compromised by such 
procedures, or remain hidden in obscure places. Cancer is also the 
consequence of defects in our own biology, which lead to the progressive 
accumulation of mutations and other genomic aberrations as cells divide 
during aging. Such accumulation can also be potently accelerated by various 
external carcinogens, some of which we have a more or less inherited tendency 
to become addicted of exposing ourselves to.  
 As human evolution only cares about whether or not we successfully 
reproduce and raise our offspring before we die, there is no advantage to be 
gained from keeping us alive after this mission is accomplished. Therefore, we 
have not developed stronger defense mechanisms against this class of disease, 
which tends to present itself at advanced ages. If we wish to extend our healthy 
lifespans, defeating cancer is critical. To do so, extensive knowledge about 
human genomic evolutionary mechanisms is required. Massive advances have 
been made as a result of the development of high-throughput sequencing 
technologies. These, in turn, generate enormous amounts of data in 
laboratories across the globe. Fully interpreting this data requires, above all 
else, efficient interaction between biologists, clinicians, and those of 
computational predisposition. 
 This thesis has focused on bioinformatical explorations, the intersect 
of biology and information science. The works included demonstrate how 
DNA and RNA-sequencing can be used to track the origin of tumors, 
nominate candidate genes that may influence cancer phenotypes, discover 
processes that generate cellular mutations and dissect the immune 
environments of tumors. A desirable end goal in line with the present work 
would be the standardized implementation of a number of these approaches 
to comprehensively genomically profile the tumors of each patient, in order to 
discover any opportunities presented by our enemy. This should ideally be 
followed by the rational customization of treatments for each unique 
condition and an instant win accompanied by a suitable victory theme. 
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